​

Anika Therapeutics (ANIK) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChartTranscripts

Anika Therapeutics Revenue Highlights

Latest Revenue (Y)

$166.66M

Latest Revenue (Q)

$38.75M

Main Segment (Y)

Joint Preservation and Restoration

Main Geography (Y)

UNITED STATES

Anika Therapeutics Revenue by Period

Anika Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$166.66M6.67%
2022-12-31$156.24M5.71%
2021-12-31$147.79M13.29%
2020-12-31$130.46M13.83%
2019-12-31$114.61M8.58%
2018-12-31$105.56M-6.93%
2017-12-31$113.42M9.71%
2016-12-31$103.38M11.16%
2015-12-31$93.00M-11.93%
2014-12-31$105.59M40.64%
2013-12-31$75.08M5.22%
2012-12-31$71.36M10.16%
2011-12-31$64.78M16.60%
2010-12-31$55.56M38.42%
2009-12-31$40.14M12.17%
2008-12-31$35.78M16.06%
2007-12-31$30.83M14.86%
2006-12-31$26.84M-10.04%
2005-12-31$29.84M12.73%
2004-12-31$26.47M71.81%
2003-12-31$15.40M16.81%
2002-12-31$13.19M16.57%
2001-12-31$11.31M-30.75%
2000-12-31$16.34M21.00%
1999-12-31$13.50M-2.88%
1998-12-31$13.90M15.83%
1997-12-31$12.00M900.00%
1996-12-31$1.20M-64.71%
1995-08-31$3.40M-27.66%
1994-08-31$4.70M113.64%
1993-08-31$2.20M-

Anika Therapeutics generated $166.66M in revenue during NA 2023, up 6.67% compared to the previous quarter, and up 157.89% compared to the same period a year ago.

Anika Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$38.75M-7.56%
2024-06-30$41.92M3.45%
2024-03-31$40.52M-5.70%
2023-12-31$42.97M3.63%
2023-09-30$41.47M-6.40%
2023-06-30$44.30M16.82%
2023-03-31$37.92M-4.29%
2022-12-31$39.62M-1.59%
2022-09-30$40.26M1.53%
2022-06-30$39.66M8.08%
2022-03-31$36.69M2.43%
2021-12-31$35.82M-9.40%
2021-09-30$39.54M3.65%
2021-06-30$38.15M11.24%
2021-03-31$34.29M4.91%
2020-12-31$32.69M3.14%
2020-09-30$31.69M3.31%
2020-06-30$30.68M-13.33%
2020-03-31$35.40M18.89%
2019-12-31$29.77M0.25%
2019-09-30$29.70M-2.37%
2019-06-30$30.42M23.04%
2019-03-31$24.72M-8.28%
2018-12-31$26.96M0.63%
2018-09-30$26.79M-12.31%
2018-06-30$30.55M43.66%
2018-03-31$21.26M-27.64%
2017-12-31$29.39M8.11%
2017-09-30$27.18M-18.76%
2017-06-30$33.46M43.09%
2017-03-31$23.39M-18.59%
2016-12-31$28.73M11.39%
2016-09-30$25.79M-2.98%
2016-06-30$26.58M19.29%
2016-03-31$22.28M-27.87%
2015-12-31$30.89M30.46%
2015-09-30$23.68M3.40%
2015-06-30$22.90M47.57%
2015-03-31$15.52M-33.26%
2014-12-31$23.25M5.44%
2014-09-30$22.06M-16.06%
2014-06-30$26.27M-22.74%
2014-03-31$34.01M60.04%
2013-12-31$21.25M19.70%
2013-09-30$17.75M-14.76%
2013-06-30$20.83M36.61%
2013-03-31$15.25M-32.55%
2012-12-31$22.61M53.09%
2012-09-30$14.77M-24.76%
2012-06-30$19.62M36.66%
2012-03-31$14.36M-22.14%
2011-12-31$18.44M-0.06%
2011-09-30$18.46M14.34%
2011-06-30$16.14M37.51%
2011-03-31$11.74M-20.27%
2010-12-31$14.72M6.15%
2010-09-30$13.87M-4.35%
2010-06-30$14.50M16.31%
2010-03-31$12.47M17.39%
2009-12-31$10.62M-1.61%
2009-09-30$10.79M13.33%
2009-06-30$9.52M3.51%
2009-03-31$9.20M2.62%
2008-12-31$8.97M-2.60%
2008-09-30$9.21M1.60%
2008-06-30$9.06M5.98%
2008-03-31$8.55M-11.20%
2007-12-31$9.63M-

Anika Therapeutics generated $38.75M in revenue during Q3 2024, up -7.56% compared to the previous quarter, and up 87.47% compared to the same period a year ago.

Anika Therapeutics Revenue Breakdown

Anika Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Joint Preservation and Restoration$54.88M$50.40M$48.59M$39.37M-
Non-Orthopedic$9.86M$7.95M$9.70M--
OA Pain Management-$97.89M$89.50M--
Licensing, Milestone and Contract Revenue-----
Product--$147.79M$130.46M$114.51M
Joint Pain Management Therapies---$83.03M-
Manufactured Product, Other---$8.06M$6.08M
Orthobiologics----$101.00M
Surgical----$5.18M
Dermal----$2.24M

Anika Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Joint Preservation and Restoration (84.77%), and Non-Orthopedic (15.23%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Non-Orthopedic$2.38M$2.36M$2.60M$3.11M$2.31M$1.84M$1.53M$2.78M$1.82M$1.82M----------
Joint Preservation and Restoration$11.95M$13.84M$15.30M$13.47M$12.66M$13.45M$14.35M$11.82M$12.10M$12.14M$13.29M$11.19M$11.88M$12.22M------
OA Pain Management----$29.33M$22.63M$23.75M$25.66M$25.74M$22.73M----------
Product---------$36.69M$35.82M$39.54M$38.15M$34.29M$32.69M$31.69M$30.68M$35.40M$29.77M$29.61M
Joint Pain Management Therapies-----------$26.15M$24.32M$19.32M$16.86M$18.44M$22.25M$25.48M--
Manufactured Product, Other-----------$2.19M$1.94M$2.76M$2.69M$1.54M$1.81M$2.02M$1.37M$1.85M
Orthopedic Joint Preservation and Restoration Care---------------$11.71M$6.62M$7.90M--
Surgical------------------$1.11M$578.00K
Dermal------------------$1.25M$417.00K
Orthobiologics------------------$26.03M$26.77M

Anika Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Joint Preservation and Restoration (83.42%), and Non-Orthopedic (16.58%).

Anika Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Europe$21.72M$20.64M$19.58M$14.18M$14.74M
UNITED STATES$123.13M$119.15M$113.83M$103.18M$90.30M

Anika Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (85.00%), and Europe (15.00%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
UNITED STATES$27.70M$29.24M$32.14M$30.83M$32.87M$27.29M$31.60M$31.09M$29.69M$26.77M$27.85M$30.91M$30.07M$25.00M$25.33M$26.41M$25.13M$26.31M$23.76M$23.51M
Europe$5.69M$5.97M$4.97M$5.42M$5.67M$5.66M$4.67M$4.88M$5.29M$5.80M$4.77M$4.24M$5.09M$5.48M$3.04M$2.95M$2.91M$5.28M$3.35M$3.94M

Anika Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (82.96%), and Europe (17.04%).

Anika Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AVNSAvanos Medical$673.30M$170.40M
AORTArtivion$354.00M$95.78M
FNAParagon 28$216.39M$61.02M
ANIKAnika Therapeutics$166.66M$38.75M
AXGNAxoGen$159.01M$48.64M
KIDSOrthoPediatrics$148.73M$52.80M
SRDXSurmodics$126.08M$30.34M
SGHTSight Sciences$81.06M$20.16M
NPCENeuroPace$65.42M$21.06M
CVRXCVRx$39.30M$13.37M
OFIXOrthofix Medical$100.00K$198.62M

ANIK Revenue FAQ

What is Anika Therapeutics’s yearly revenue?

Anika Therapeutics's yearly revenue for 2023 was $166.66M, representing an increase of 6.67% compared to 2022. The company's yearly revenue for 2022 was $156.24M, representing an increase of 5.71% compared to 2021. ANIK's yearly revenue for 2021 was $147.79M, representing an increase of 13.29% compared to 2020.

What is Anika Therapeutics’s quarterly revenue?

Anika Therapeutics's quarterly revenue for Q3 2024 was $38.75M, a -7.56% decrease from the previous quarter (Q2 2024), and a -6.54% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $41.92M, a 3.45% increase from the previous quarter (Q1 2024), and a -5.37% decrease year-over-year (Q2 2023). ANIK's quarterly revenue for Q1 2024 was $40.52M, a -5.70% decrease from the previous quarter (Q4 2023), and a 6.85% increase year-over-year (Q1 2023).

What is Anika Therapeutics’s revenue growth rate?

Anika Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 12.77%, and for the last 5 years (2019-2023) was 45.42%.

What are Anika Therapeutics’s revenue streams?

Anika Therapeutics's revenue streams in c 23 are Joint Preservation and Restoration, and Non-Orthopedic. Joint Preservation and Restoration generated $54.88M in revenue, accounting 84.77% of the company's total revenue, up 8.88% year-over-year. Non-Orthopedic generated $9.86M in revenue, accounting 15.23% of the company's total revenue, up 24.02% year-over-year.

What is Anika Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Anika Therapeutics was Joint Preservation and Restoration. This segment made a revenue of $54.88M, representing 84.77% of the company's total revenue.